36 results about "Rheumatoide arthritis" patented technology

The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis.

The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition selected from the group consisting of pains, including the phase 1 pain and the phase 2 pain, anxiety and stress. The composition is particularly beneficial to alleviating or getting rid of the pain and anxiety which significantly lower quality of life of patients with end-stage cancer. The composition of this invention is also useful for treatment of pains, including the phase 1 pain and the phase 2 pain, and inflammation which accompany arthritis or diseases in the junctions of bones (e.g. rheumatoid arthritis, osteoarthritis, frozen shoulder, sports injuries such as tennis elbow and baseball shoulder, and low back pain).

The name of the invention is application of an anti-CiP antibody in diagnosis of an early rheumatoid arthritis. The invention provides a method for CiP and analogues thereof for detection of the early rheumatoid arthritis (RA). A polypeptide antigen can be specifically combined with a specific antibody inside a body of a sufferer with the early RA, the anti-CiP antibody has high sensitivity and specificity, and has high positive rate in the sufferer with the early RA having negative IgM-RF or anti-CCP antibody, and detection results of an anti-keratin antibody (AKA) and an antiperinuclear factor (APF). Auxiliary diagnosis of the sufferer with the negative IgM-RF antibody or the negative anti-CCP antibody is facilitated.

Linderolide H for treating immune inflammations is used to prepare drugs for treating rheumatoid arthritis; by using terfenadine and diclofenac as controls, Linderolide H has exact treatment effect; the application of Linderolide H related herein in the preparation of drugs for treating rheumatoid arthritis is disclosed for the first time; since a framework is of brand-new type and the inhibitory activity for rheumatoid arthritis is unexpectedly high, there is no chance for other compounds to give any indication and outstanding practical characteristics are provided; in addition, Linderolide H has significant progress in preventing and treating rheumatoid arthritis.

The invention discloses a blood marker-PGK1 for rheumatoid arthritis clinical diagnosis, and discloses a reagent for rheumatoid arthritis clinical diagnosis. The reagent comprises a PGK1 antibody, an HRP-IgG antibody and a conventional reagent in a blood diagnosis reagent. The conventional reagent in the blood diagnosis reagent comprises a carbonate buffer solution, PBST washing liquor, confining liquid, a developing solution and a stop solution. The prepared detection reagent has the advantages of being high in sensitivity, high in specificity and the like and is capable of being widely applied to preliminary survey and health examination of clinical rheumatoid arthritis and providing a reliable basis for clinical diagnosis.

The invention relates to Nardoaristolones A for treating immune inflammation and the Nardoaristolones can be used for preparing medicines for treating rheumatoid arthritis. Terfenadine and diclofenac sodium are taken as control, and the curative effect of Nardoaristolones A is exact. The use of Nardoaristolones A for preparing medicines for treating rheumatoid arthritis provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, Nardoaristolones A has remarkable substantive characteristics and obviously has remarkable progress for preventing and treating rheumatoid arthritis.

According to the invention, 26 types of proteins have differential expression in immune complexes of serums of an RA (rheumatoid arthritis) patient and a normal collator through the mass spectrometry, wherein LBP (lipopolysaccharide binding protein) is proved to be increased in RA circulating immune complexes; according to a further research, LBP is a specificity serum marker of RA and has an important role in assessing and diagnosing activity of RA. The invention aims to apply the enzyme linked immunosorbent assay to detect the LBP level, diagnose RA and assess the disease activity.

The invention discloses a medicament composition for treating rheumatoid arthritis, which is a preparation mainly prepared from the raw materials such as black ants, tripterygium wilfordii, scorpio, geranium wilfordii, rhizoma dioscoreae nipponicae, menispermaceae roots, gentiana macrophylla, turmeric and liquorice. The medicament has the advantages of simple and unique prescription, low price and remarkable efficacy. Clinical study confirms that the medicament can rapidly improve pain, swelling, morning stiffness symptoms of patients without obvious toxic-side effects. The invention also discloses a method for preparing the medicament. The medicament is obtained by grinding or extracting Chinese medicaments with solvents respectively, performing other pretreatment and then compounding the obtained products pro rata according to the different characteristics of each Chinese medicament.

The invention relates to the technical field of sports apparatus, which discloses a rheumatoid arthritis sports healing machine. In order to solve the problem that the prior sports apparatus is not suitable for rheumatoid arthritis patients, the rheumatoid arthritis sports healing machine adopts the technical proposal that the healing machine comprises a sports device arranged on a base (5), a fixed foot pedal vehicle, a supporting frame and a simple vehicle wheel (4). The rheumatoid arthritis sports healing machine is characterized in that the supporting frame comprises a front supporting frame (6), a back supporting frame (10) and a mechanism (9) for regulating pressure (9); the upper end of the front supporting frame (6) is connected with a vehicle body (7), while the lower end is connected with the base (5); the back supporting frame (10) comprises a mounting frame and a rotating roller, the mounting frame is connected with the base (5) fixedly, the rotating roller is connected with the mounting frame rotatablely, and the rotating roller is positioned at the bottom of the vehicle wheel (4); and the mechanism(9) for regulating the pressure is arranged between the vehicle body (7) and the base (5). The rheumatoid arthritis sports healing machine has the advantages of having a plurality of sports apparatus, carrying out the slightest sports, and the like.

The invention provides an application of trillium tschonoskii total saponins in preparation of a medicine for treating rheumatoid arthritis. The effect of the trillium tschonoskii total saponins on adjuvant-induced arthritis model rat inflammation is researched from an NOD-like receptor protein 3 / cysteine aspartic protease 1 pathway. The SD rats are randomly divided into a blank group, a model group, a tripterygium glycosides group, a trillium tschonoskii total saponin low-dose group, a trillium tschonoskii total saponin medium-dose group and a trillium tschonoskii total saponin high-dose group, and each group comprises six rats. The result shows that compared with the Control group, the foot swelling degree, the arthritis score, the serum TNF-alpha, IL-1beta and IL-6 levels of the AA group, the NLRP3 protein expression level in synovial tissues and the NLRP3, ASC and Caspase-1 protein levels in ankle joints are all remarkably improved; knee joint synovial cell proliferation, interstitial edema and inflammatory cell infiltration of the AA group rats; and after treatment with TG and TTM with different doses, the indexes are all improved to different degrees.

The invention discloses a compound traditional Chinese medicine for treating acute-phase rheumatoid arthritis. The compound traditional Chinese medicine comprises raw materials of milkvetch root, roasted thinleaf milkwort root-bark, stem of noble dendrobium, achyranthes root, Japanese honeysuckle stem, Szechuan lovage rhizome, processed common monkshood root, Chinese waxgourd peel, glabrous greenbrier rhizome, and rhizoma corydalis; the milkvetch root in the formula is used as a sovereign drug, which is an effective medicine for invigorating qi, and is used for maintaining vital qi to lead other medicines to illness stations, thereby removing obstruction and stagnation and driving away pathological factors. The achyranthes root is capable of nourishing Yin and strengthening Yang, strengthening tendons and bones, and removing blood stasis to stop blood stasis, and is good at treating inhibited bending and stretching of joints; the stem of noble dendrobium is capable of nourishing Yin to produce body fluid; the thinleaf milkwort root-bark is capable of invigorating heart and kidney; the medicines are used as ministerial drugs which can eliminate an inward spreading path of pathogenic factors, and strengthen unaffected parts, and can remove phlegm and eliminate pains and swelling. The processed common monkshood root is capable of dispersing cold and relieving pain; the Szechuan lovage rhizome and the rhizoma corydalis are capable of promoting blood and Qi circulation to relieve pains to achieve an effect of removing stasis and pains automatically by promoting blood and Qi circulation; the Chinese waxgourd peel and the glabrous greenbrier rhizome are capable of eliminating dampness to relieve pains, easing joint movement and eliminating swelling; the Japanese honeysuckle stem is capable of clearing away heat and toxic materials, can eliminate painful swelling of joints caused by heat generated by stases, and can restrict the warm nature of the milkvetch root, and these medicines are used as adjuvant drugs. All the raw medicinal materials work together to achieve the effects of promoting circulation of blood to remove arthralgia, relieving swelling and pains while taking care of the stomach. All kinds of medicines are combined to achieve the functions of strengthening healthy energy to eliminate swelling, and dispelling cold and relieving pains.

The invention provides Gypensapogenin A for treating immune inflammation and application of Gypensapogenin A in a medicine for treating rheumatoid arthritis. Compared with terfenadine and diclofenac sodium, Gypensapogenin A has accurate curative effects. The application of Gypensapogenin B in preparing the medicine for treating rheumatoid arthritis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the rheumatoid arthritis inhibiting activity of Gypensapogenin A is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin A has outstanding actual characteristics. Meanwhile, Gypensapogenin A has outstanding progress when being used for preventing and treating rheumatoid arthritis.

The invention provides the application of berberine in the preparation of medicines for preventing and treating rheumatoid arthritis. The invention adopts the berberine to carry out the animal efficacy test, and the result shows that the berberine can inhibit the clinical onset of collagen-induced arthritis, and obviously inhibit the severity and incidence rate of the onset. And can down-regulate tumor necrosis factor α, interleukin 17, interferon γ in spleen cell supernatant, inhibit the secretion of pro-inflammatory cytokines TNF-α, IFN-γ and IL-17, so as to prepare drugs for preventing and treating rheumatoid arthritis, It has great clinical application value. The medicine is a pharmaceutical composition made of berberine as an active ingredient and conventional pharmaceutical excipients, including tablets, dispersible tablets, buccal tablets, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, Granules, injections, powder injections or aerosols.